DEVICE-INDEPENDENT QUANTUM KEY DISTRIBUTION
    31.
    发明公开

    公开(公告)号:US20230353350A1

    公开(公告)日:2023-11-02

    申请号:US17998661

    申请日:2021-05-12

    IPC分类号: H04L9/08

    CPC分类号: H04L9/0858

    摘要: The invention relates to a method for device-independent quantum key generation and distribution between a first and a second receiver, the method comprising the steps of:

    a) Generating an entangled information pair, comprising two entangled quantum moieties that have at least one quantum state entangled with each other, such as a polarization,
    b) Transmitting a first entangled quantum moiety of the two entangled quantum moieties to the first receiver (A) and a second entangled quantum moiety of the two entangled quantum moieties to the second receiver (B), and measuring the quantum states of the entangled moieties with a set of selected detection settings chosen randomly at each receiver
    c) In a modification step, assigning each measurement value b1 measured with a detection setting B1 a complementary value





    b
    1






    according to a noise-probability p, wherein the noise-probability p is larger than 0 and lower than 1, such that a modified plurality of measurement values







    b
    1


    ˜





    is obtained,
    d) Generating a final shared quantum key from the modified plurality measurements values







    b
    1


    ˜





    and from a plurality of measurement values a0 measured with a detection setting A0 at the first receiver (A).

    ARENAVIRUSES AS VECTORS
    36.
    发明申请

    公开(公告)号:US20220380805A1

    公开(公告)日:2022-12-01

    申请号:US17772996

    申请日:2020-11-06

    IPC分类号: C12N15/86 A61K39/12

    摘要: The present application relates to arenavirus particles containing a genome engineered such that an arenaviral open reading frame (“ORF”) is sequestered into two or more functional fragments and these fragments are expressed from two or more viral mRNA transcripts. The arenavirus particles described herein are genetically stable and provide high-level transgene expression. In certain embodiments, the arenavirus particles are tri-segmented. In particular, described herein is a nucleotide sequence comprising one or more ORFs comprising a nucleotide sequence encoding a functional fragment of arenavirus GP, NP, L or Z. Also described herein is an arenavirus particle containing a genome engineered such that an arenaviral ORF is sequestered into two or more functional fragments and these fragments are expressed from two or more viral mRNA transcripts. Also described herein is an arenavirus genomic or antigenomic segment engineered such that the transcription thereof results in one or more mRNA transcripts comprising a nucleotide sequence encoding a functional fragment of arenavirus GP, NP, L or Z. The arenavirus particles described herein may be suitable for vaccines and/or treatment of diseases and/or for the use in immunotherapies.

    FORCE SENSING DEVICE, MEDICAL ENDODEVICE AND PROCESS OF USING SUCH ENDODEVICE

    公开(公告)号:US20210267709A1

    公开(公告)日:2021-09-02

    申请号:US17254737

    申请日:2019-06-21

    IPC分类号: A61B90/00 A61B1/00 A61B1/05

    摘要: A force sensing device is disclosed that includes a housing tip, a plurality of sensors stationarily spaced from each other, and a spring element connecting the housing tip to the sensors such that moving the housing tip and the sensor relative to each other causes a resilient deformation of the spring element. The spring element is configured to arrange the housing tip in a zero position relative to the sensors by a spring force of the spring element. The force sensing device is also equipped with a spring tensioning structure configured to adapt the spring force of the spring element.

    Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids

    公开(公告)号:US11091591B2

    公开(公告)日:2021-08-17

    申请号:US15760398

    申请日:2016-09-14

    IPC分类号: C07H15/12 C08G69/48 A61P25/00

    摘要: The invention relates to carbohydrate ligands and moieties, respectively, mimicking glycoepitopes comprised by glycosphingolipids of the nervous system, particularly glycoepitopes comprised by glycosphingolipids of the cerebroside, the globoside-, the ganglioside- and the sulfoglucuronyl paragloboside type, which are bound by anti-glycan antibodies associated with neurological diseases. The invention further relates to the use of these carbohydrate ligands/moieties, in diagnosis as well as for the treatment of neurological diseases associated with anti-glycan antibodies. In particular, the invention relates to compounds of formula (I) and (II) and to therapeutically acceptable polymers comprising a multitude of these compounds, including polymers with loading of one compound of formula (I) or (II) or combinations of several compounds of formula (I), and/or (II). The compounds of formula (I) are defined as: wherein RI1 is Z or wherein RI2 is H, SO3H, or wherein RI3 is H or wherein RI4 is H or wherein RI5 and RI6 are independently H or wherein RI7 is H or and compounds of formula (II) are defined as: wherein RII1 is Z or wherein RII2 is Z or wherein Z is —N(Ra)—A—B—CH2—(CH2)q—SH, wherein Ra is H, C1-C4-alky, C1-C4alkoxy, CH2C6H5, CH2CH2C6H5, OCH2C6H5, or OCH2CH2C6H5; A is C1-C7-alkylene, C1-C7-alkoxy, C1-C4-alkyl—(OCH2CH2)pO—C1-C4-alkyl, or C1-C7-alkoxy-Rb, wherein Rb is an optionally substituted aryl or an optionally substituted heteroaryl, and wherein p is 0 to 6, preferably p is 1, 2 or 3, and further preferably p is 1; B is NHC(O), S or CH2; q is 0 to 6, preferably q is 1, 2, 3 or 4, and further preferably q is 1 or 2.